These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 31970549)

  • 1. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G; Bertoldi I; Rossini M
    Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
    Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
    Front Immunol; 2021; 12():738481. PubMed ID: 34630419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
    Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
    Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
    Abdulrahim H; Sharlala H; Adebajo AO
    Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
    [No Abstract]   [Full Text] [Related]  

  • 7. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis.
    Crispino N; Ciccia F
    Clin Exp Rheumatol; 2021; 39(3):668-675. PubMed ID: 33200731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
    Hu L; Liu R; Zhang L
    Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib in psoriatic arthritis.
    Wang TS; Tsai TF
    Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
    Ibrahim SSA; Salama MA; Selima E; Shehata RR
    Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
    Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
    Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
    Tanaka Y
    J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [JAK inhibitor].
    Yamaoka K; Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.